Takeda San Francisco names new vice president of antibody research

Dr Landes will be responsible for directing the discovery and preclinical development of therapeutic antibodies at Takeda’s antibody IND engine and center of excellence for biologics.

Dr Landes has previously held executive positions with major biopharmaceutical companies, including Lexicon Pharmaceuticals, Abgenix and Genzyme.

Dr Landes holds a BA in chemistry and PhD in biochemistry from the University of Kansas and was a post-doctoral scholar at University of California, Los Angeles.

Mary Haak-Frendscho, president and chief scientific officer of Takeda San Francisco, said: “Greg’s extensive experience covers key aspects of antibody drug discovery and development. He will play an important role as we expand Takeda’s biologics R&D capabilities in order to realize our goals of advancing superior therapeutics to contribute to the health of individuals.”